Literature DB >> 31155338

Abandoning the Notion of Non-Small Cell Lung Cancer.

Valeria Relli1, Marco Trerotola2, Emanuela Guerra2, Saverio Alberti3.   

Abstract

Non-small cell lung cancers (NSCLCs) represent 85% of lung tumors. NSCLCs encompass multiple cancer types, such as adenocarcinomas (LUADs), squamous cell cancers (LUSCs), and large cell cancers. Among them, LUADs and LUSCs are the largest NSCLC subgroups. LUADs and LUSCs appear sharply distinct at the transcriptomic level, as well as for cellular control networks. LUADs show distinct genetic drivers and divergent prognostic profiles versus LUSCs. Therapeutic clinical trials in NSCLC indicate differential LUAD versus LUSC response to treatments. Hence, LUAD and LUSC appear to be vastly distinct diseases at the molecular, pathological, and clinical level. Abandoning the notion of NSCLC may critically help in developing novel, more effective subtype-specific molecular alteration-targeted therapeutic procedures.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  lung cancer; prognosis; therapy; tumor classification

Mesh:

Substances:

Year:  2019        PMID: 31155338     DOI: 10.1016/j.molmed.2019.04.012

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  59 in total

1.  Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival.

Authors:  Sen Yang; Dongfang Tang; Yu C Zhao; Hongliang Liu; Sheng Luo; Thomas E Stinchcombe; Carolyn Glass; Li Su; Sipeng Shen; David C Christiani; Qiming Wang; Qingyi Wei
Journal:  Int J Cancer       Date:  2019-12-19       Impact factor: 7.396

Review 2.  Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis.

Authors:  Shaofang Feng; Huiwen Mu; Rong Hou; Yunxin Liu; Jianjun Zou; Zheng Zhao; Yubing Zhu
Journal:  Int J Clin Oncol       Date:  2022-05-23       Impact factor: 3.402

Review 3.  Long non‑coding RNA PART1: dual role in cancer.

Authors:  Rui Ran; Chao-Yang Gong; Zhi-Qiang Wang; Wen-Ming Zhou; Shun-Bai Zhang; Yong-Qiang Shi; Chun-Wei Ma; Hai-Hong Zhang
Journal:  Hum Cell       Date:  2022-07-21       Impact factor: 4.374

4.  Serum-derived extracellular vesicles promote the growth and metastasis of non-small cell lung cancer by delivering the m6A methylation regulator HNRNPC through the regulation of DLGAP5.

Authors:  Shanshan Shi; Tong Wu; Zechen Ma; Xiudi Zhang; Ke Xu; Qi Tian; Liming Gao; Xiaobo Yin; Shufeng Xu; Shengbo Yang
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-29       Impact factor: 4.322

5.  Cancer-Testis Antigen LDH-C4 in Tissue, Serum, and Serum-Derived Exosomes Serves as a Promising Biomarker in Lung Adenocarcinoma.

Authors:  Wei Peng; Jin Chen; Yanping Xiao; Guangjian Su; Yan Chen; Zhaolei Cui
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

6.  Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway.

Authors:  Yue Wu; Jiajing Zhang; Changping Yun; Chenchen Dong; Ye Tian
Journal:  Comput Math Methods Med       Date:  2022-06-28       Impact factor: 2.809

7.  Genetic variants of DOCK2, EPHB1 and VAV2 in the natural killer cell-related pathway are associated with non-small cell lung cancer survival.

Authors:  Hailei Du; Lihua Liu; Hongliang Liu; Sheng Luo; Edward F Patz; Carolyn Glass; Li Su; Mulong Du; David C Christiani; Qingyi Wei
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

8.  Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.

Authors:  Peng Cao; Sanlan Wu; Wei Guo; Qilin Zhang; Weijing Gong; Qiang Li; Rui Zhang; Xiaorong Dong; Shuangbing Xu; Yani Liu; Shaojun Shi; Yifei Huang; Yu Zhang
Journal:  Metabolomics       Date:  2021-11-03       Impact factor: 4.290

9.  Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.

Authors:  Joe W Chen; Joseph Dhahbi
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

10.  Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy.

Authors:  Xiaodong Yang; Yuexin Zheng; Zhihai Han; Xiliang Zhang
Journal:  BMC Cancer       Date:  2021-06-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.